报告题目：Nano-liquid biopsy: new strategy towards cancer diagnosis and treatment response
报 告 人：王玉玲 副教授
澳大利亚 麦考瑞大学 分子科学系
腾讯会议：668 200 163
邀 请 人：徐抒平 教授
Cancer is a heterogeneous disease which manifests as different molecular subtypes due to the complex nature of tumor initiation, progression and metastasis. Non-invasive analysis of cancer biomarkers such as circulating pro-teins, DNAs, exosomes and cells from body fluids (so called liquid biopsy) is in high demand and important for cancer diagnostics and treatment as it is the key to achieve the original and intact information from the cells. Thus, non-invasive analysis of circulating biomarkers has the benefit of rapid, low-cost and little inconvenience to the patients. In this lecture, Dr Wang will talk about the use of nano-liquid biopsy, a new strategy for cancer diagnosis and treatment response, from the rational design and synthesis of a suite of multifunctional nanoparti-cles (NPs), establishment of rapid sensor platform (e.g. microfluidic device), towards the simultaneously and se-lectively detecting a broad panel of circulating cancer biomarkers. The key technique used in her study is surface-enhanced Raman spectroscopy (SERS), which is a powerful analytical tool for molecular analysis. Monitoring of the phenotypes and glycan profiles of circulating tumor cells, or exosomes in response to targeted therapy will be involved.
Yuling Wang is currently an Associate Professor in the Department of Molecular Sciences, Macquarie University (Sydney). She received her PhD degree from Changchun Institute of Applied Chemistry, Chinese Academy of Sciences in 2009. She was then awarded an Alexander von Humboldt (AvH) fellowship (2010) and the Individual Grant Fellowship from German Research Foundation (DFG, 2012), working in University of Duisburg-Essen, Germany. In 2014, she received the ARC Discovery Early Career Research Award (DECRA), worked in the Uni-versity of Queensland. Since joined at Macquarie University in 2017, she has established her group. Her research is mainly focused on plasmonic nanostructures for surface-enhanced Raman spectroscopy; biomarker sensing for point-of-care diagnostics and personalized nanomedicine.